Whole exome sequencing in patients with childhood‐onset systemic lupus erythematosus: Results from a Croatian national study

Mario Sestan,Todor Arsov,Nastasia Kifer,Marijan Frkovic,Danica Grguric,Julia Ellyard,Matthew Cook,Carola G. Vinuesa,Marija Jelusic
DOI: https://doi.org/10.1111/sji.13411
2024-10-10
Scandinavian Journal of Immunology
Abstract:We performed WES on 17 selected trios (sometimes including other family members) where the proband had severe, atypical features, therapy resistance, familial patterns and/or syndromic characteristics. This identified 17 novel or low‐frequency variants in 7 patients. The purpose of this study was to identify new and low‐frequency gene variants using whole exome sequencing (WES) in patients with childhood‐onset systemic lupus erythematosus (cSLE), that may be involved in the pathogenesis of SLE. We performed WES on selected 17 trios (in some cases including other informative family members) in which the proband presented with severe, atypical clinical features, resistance to conventional therapy, a family pattern of occurrence and/or syndromic characteristics. After performing WES and analysis of gene variants, 17 novel and/or low‐frequency variants were identified in 7 patients. One variant was classified as pathogenic (KMT2D, NM_003482.3:c.8626delC, predicted to truncate the protein p.(Gln2876Serfs*34)) and two as likely pathogenic according to the American College of Medical Genetics and Genomics classification guidelines (ADAR, NM_001111.3:c.2815A>G, predicted to encode p.(Ile939Val); BLK, NM_001715.2:c.211G>A, predicted to encode p.(Ala71Thr)). The other variants remain of uncertain significance at this point of time. WES is an important diagnostic and research instrument, producing a growing list of likely genes and gene variants that may be of relevance in the pathogenesis of cSLE and potentially point to novel therapeutic targets.
immunology
What problem does this paper attempt to address?